SRD5A2 Expression Is a Predictor of Response to Finasteride in the MTOPS Trial
March 2023
in “
The Journal of Urology
”
TLDR Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
The MTOPS trial investigated the effect of finasteride, doxazosin, or their combination on urinary symptoms in men with benign prostatic hyperplasia (BPH). Analysis of prostate biopsies and clinical data from 82 participants revealed that higher expression of SRD5A2, an enzyme regulated epigenetically, was associated with a better response to finasteride treatment. Specifically, men with higher SRD5A2 expression showed greater improvement in urinary symptoms, as measured by the AUA symptom score. This finding suggests that SRD5A2 expression could be a predictor of response to finasteride, potentially aiding in the development of precision medicine approaches for BPH treatment.